Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Purpose. To investigate the effect of microparticle size on gastrointestinal tissue uptake.
Methods. Biodegradable microparticles of various sizes using polylactic polyglycolic acid (50:50) co-polymer (100 nm, 500 nm, 1µm, and 10 µm) and bovine serum albumin as a model protein were formulated by water-in-oil-in-water emulsion solvent evaporation technique. The uptake of microparticles was studied in rat in situ intestinal loop model and quantitatively analyzed for efficiency of uptake.
Results. In general, the efficiency of uptake of 100 nm size particles by the intestinal tissue was 15–250 fold higher compared to larger size microparticles. The efficiency of uptake was dependent on the type of tissue, such as Peyer's patch and non patch as well as on the location of the tissue collected i.e. duodenum or ileum. Depending on the size of microparticles, the Peyer's patch tissue had 2–200 fold higher uptake of particles than the non-patch tissue collected from the same region of the intestine. Histological evaluation of the tissue sections demonstrated that 100 nm particles were diffused throughout the submucosal layers while the larger size nano/microparticles were predominantly localized in the epithelial lining of the tissue.
Conclusions. There is a microparticle size dependent exclusion phenomena in the gastrointestinal mucosal tissue with 100 nm size particles showing significantly greater tissue uptake. This has important implications in designing of nanoparticle-based oral drug delivery systems, such as an oral vaccine system.
- P. Couvreur, B. Kante, M. Roland and P. Speiser. J. Pharm. Sci. 68(12):1521–1524 (1979).
- P. Couvreur, V. Lenaerts, D. Leyh, P. Guiot and M. Roland. In Microspheres and Drug Therapy. Pharmacuticals, Immunological and Medical Aspects. Edited by S. S. Davis, L. Illum, J. G. McVie and E. Tomlinson., Elsevier Science Publishers B. V. 103–115 (1984).
- J. Kreuter. Inter. J. Pharm. 14:43–58 (1983).
- L. Illum, S. S. Davis, R. H. Muller, E. Mak and P. West. Life Sci. 40:367–374 (1987).
- P. Maincent, R. Le Verge, P. A. Sado, P. Couvreur and J. P. Devissaguet. J. Pharm. Sci. 75:955–958 (1986).
- P. A. Kramer and T. Burnstein. Life Sci. 19:515–520 (1976).
- J. J. Marty, R. C. Oppenheim and P. P. Speiser. Pharm. Acta Helv. 53:17–23 (1978).
- C. M. Adeyeye, J. D. Bricker, V. D. Vilivalam and W. I. Smith. Pharm. Res. 13:784–793 (1996).
- J. Mestecky, Z. Moldoveanu, M. Novak, W. Q. Huang, R. M. Gilley, J. K. Staas, D. Schafer and R. W. Compans. J. Control. Rel. 28:131–141 (1994).
- C. A. Gilligan and A. L. Wan Po. Inter. J. Pharm. 75:1–24 (1991).
- D. T. O'Hagan, K. J. Palin and S. S. Davis. CRC Critical Reviews in Therapeutic Drug Carrier Systems. 4:197–220 (1987).
- H. O. Alpar, W. N. Field, R. Hyde and D. A. Lewis, J. Pharm. Pharmacol. 41:194–196 (1989).
- M. E. LeFevre, J. W. Vanderhoff, J. A. Laissue and D. D. Joel. Experientia.. 34:120–122 (1978).
- A. T. Florence and P. U. Jani. In Pharmaceutical Particulate Carriers. Therapeutic Application. Edited by Alain Rolland, Marcel Dekker Inc. 61:65–108 (1993).
- J. Pappo and T. H. Ermak. Clin. Exp. Immunol. 76:144–148 (1989).
- E. Sanders and C. T. Ashworth. Exp. Cell Res. 22:137–145 (1961).
- P. Jani, G. W. Halbert, J. Langridge and A. T. Florence. J. Pharm. Pharmacol. 41:809–812 (1989).
- P. Jani, G. W. Halbert, J. Langridge and A. T. Florence. J. Pharm. Pharmacol. 42:821–826 (1990).
- D. S. Cox and M. A. Taubman. Int. Archs Allergy Appl. Immun. 75:126–131 (1984).
- O. Strannegard and A. Yurchision. Int. Arch. Allergy. 35:579–590 (1969).
- J. R. McGhee, J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa and H. Kiyono. Vaccine 10:75–88 (1992).
- M. E. LeFevre and D. D. Joel. In Intestinal Toxicology. Edited by C. M. Schiller. Raven Press. 45–56 (1984).
- J. H. Eldridge, J. K. Staas, J. A. Meulbroek, J. R. McGhee, T. R. Tice and R. M. Gilley. Mol. Immunol. 28:287–294 (1991).
- J. P. Ebel. Pharm. Res. 7:848–451 (1990).
- A. M. Hillery, P. U. Jani and A. T. Florence. J. Drug Targetting. 2:151–156 (1994).
- H. Tomizawa, Y. Aramaki, Y. Fujii, T. Hara, N. Suzuki, K. Yachi, H. Kikuchi and S. Tsuchiya. Pharm. Res. 10:549–552 (1993).
- R. H. Muller. In Colloidal carriers for controlled drug delivery and targeting. CRC Press, Boston. 43–45 (1991).
- J. H. Eldridge, C. J. Hammond, J. A. Muelbroek, J. K. Staas, R. M. Gilley and T. R. Tice. J. Control. Rel. 11:205–214 (1990).
- C. Damge, C. Michel, M. Aprahamian, P. Couvreur and J. P. Devissaguet. J. Control. Rel. 13:233–237 (1990).
- M. Aprahamian, C. Michel, W. Humbert, J. P. Devissaguet and C. Damge. Bio. Cell. 61:69–74 (1987).
- Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
Volume 13, Issue 12 , pp 1838-1845
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- drug delivery
- Peyer's patches
- size exclusion
- Industry Sectors